Recent Interviews

Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".

Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".

John Jeffrey, CEO, Saturn Oil + Gas Inc.

John Jeffrey
CEO | Saturn Oil + Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary (CAN)


Saturn Oil + Gas CEO John Jeffrey: "Acquisition has increased production by 2,000%"

26. July 2021 | 13:55 CET

BioNTech, Cardiol Therapeutics, CureVac - What is next?

  • Biotechnology
Photo credits:

Are you smiling or shaking your head? Both are easily understandable reactions that investors might have in light of the latest statements from the Deutsches Aktien Institut (DAI). The DAI calls for better conditions for IPOs of growth companies to prevent such companies from migrating to foreign stock exchanges, as happened with BioNTech, among others. "Especially companies with specialized business models and high financing needs are dependent on foreign investors," explained Uta-Bettina von Altenbockum. However, this is not a new phenomenon either. Other countries have been creating better framework conditions for corporations and better tax incentives for investors for a long time. Own goal. What opportunities are there?

time to read: 3 minutes by Carsten Mainitz



Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author

BIONTECH SE - New all-time high

The BioNTech share recently reached a new all-time high. The announcement by the US to buy another 200 million doses of the Corona vaccine from manufacturers BioNTech and Pfizer triggered the share price surge. According to the announcement, the US government is preparing for the vaccination of younger children and booster shots for adults. Pfizer said just over half of the doses would be delivered by the end of the year and the rest by April 2022. That brings the total orders to 500 million units.

The potential vaccination of children and adolescents and booster shots will continue to keep vaccine manufacturers' coffers ringing in the months ahead. In addition, there is a high probability that with the emergence of more and more new covid variants, vaccinations will be with us for a long time to come. The European Medicines Agency (EMA) recently voted to approve a second Corona vaccine for children and adolescents. As a result, after the vaccine from BioNTech, the preparation from Moderna could now also be used. The EU Commission still has to approve the approval, but this is considered a formality.

With a share price of around USD 282, BioNTech is currently valued at USD 58 billion. We assume that analysts will soon further increase the price targets for the shares; according to the prevailing opinion, the title is now exhausted. However, the latest developments and the resulting potential are probably not yet priced into the investment judgments. Looking at some experts' estimates, which assume earnings this year and next year in the order of USD 7 billion each, the stock is moderately valued with a P/E ratio of 8 to 9. Of course, the question is how sustainable the profits generated are. The bottom line is that the stock offers a good risk-reward ratio.

CARDIOL THERAPEUTICS INC - Change in the Board of Directors

Cardiol Therapeutics is breaking new ground in the therapy of inflammatory heart diseases. The Canadians are relying on cannabidiol (CBD) for therapeutic trials. A body of scientific evidence exists that cites the use of cannabidiol as beneficial as an anti-inflammatory agent.

The Company's lead product, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is currently being evaluated in a Phase II/III outcomes study in hospitalized patients who tested positive for the Covid-19 virus. This potential pivotal study is designed to assess the efficacy and safety of CardiolRx as a cardioprotective therapeutic to reduce mortality and major cardiovascular events in Covid-19 patients with pre-existing cardiovascular disease or risk factors for cardiovascular disease. The study is also to evaluate the impact of CardiolRx on key markers of inflammatory heart disease.

Due to age, the Company recently announced a change within the board. Dr. Guillermo Torre-Amione has now been appointed as the new Chairman. Dr. Torre-Amione has served as an independent director of Cardiol since August 2018 and now takes over from Dr. Eldon Smith, who has held the role of Chairman since Cardiol's inception and is now retiring. Dr. Guillermo Torre-Amione is a board-certified specialist in cardiovascular disease and advanced heart failure/transplant cardiology.

Cardiol filed for listing on NASDAQ in March 2021. Inclusion in the US index is expected to result in a significant valuation boost for the stock. To further develop the Company, the Canadians raised more than CAD 50 million on the capital market in the last 12 months. Currently, a price of CAD 2.72 is being called for the shares, which means that the Company is valued at just under CAD 120 million. If the analysts at GBC are to be believed, the share has an upside potential of up to CAD 15.77!

CUREVAC NV - What does the future hold?

Opportunity and risk are two sides of the same coin. While Mainz-based BioNTech and partner Pfizer are writing a breathtaking success story, the Tübingen-based vaccine developer CureVac is on the downside. Some time ago, the Süddeutsche reported that the vaccine's effectiveness was only around 48%. As a result, the German government announced that the CureVac vaccine would no longer be included in the current campaign. Unsurprisingly, Curevac's share price plummeted as a result and has not recovered significantly to date. At a current share price of EUR 46, the Company is valued at around EUR 8 billion. The market will certainly take a while to price in the changed situation. Should the Company fail to launch the vaccine, the current valuation is far too high.

No opportunity without risk. Investors should keep this in mind, especially with biotech stocks. Biontech certainly offers the best risk-reward ratio. In the case of Cardiol, a reassessment should begin in the event of success. In our opinion, the risks outweigh the rewards for CureVac.


Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author

Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.

Related comments:

15. September 2021 | 12:17 CET | by Nico Popp

Valneva, Cardiol Therapeutics, Sartorius: Healthy returns in every market phase

  • Biotechnology

The pandemic has given the healthcare sector a boost. If people were still somewhat hesitant to talk about the digitization of the healthcare system in 2019, the epidemic has clearly revealed where the weaknesses are. New drugs and procedures could also be tested under the new framework conditions. If nothing else, the industry is getting renewed attention as a result. We outline three companies and explain whether the shares have prospects or not.


14. September 2021 | 13:10 CET | by Nico Popp

BioNTech, Defence Therapeutics, Valneva: Here, the overall market (almost) does not matter

  • Biotechnology

Is the crash coming or not? Meanwhile, even Wall Street banks are warning of an imminent crash event. Many commentators are jumping on the bandwagon. The reasons: Delta variation, supply problems and inflation, and an economy that could suffer. But if you compare the crashes of the past years, one thing becomes clear: Only the fewest price setbacks came with notice! We present three stocks that many investors believe can combine growth and security.


10. September 2021 | 12:43 CET | by André Will-Laudien

NanoRepro, XPhyto Therapeutics, BioNTech, Valneva - The next biotech wave is rolling!

  • Biotechnology

So far, vaccine manufacturers can maintain their high valuation because the next wave of new infections is rolling in. In Germany, tests will be subject to fees starting in October, making public life more expensive for those who want to participate. In surveys, most German citizens have expressed support for fee-based testing; probably, the populations here should be separated into "vaccinated" and "unvaccinated" to indicate general opinion accurately. Four interesting values benefit from the current situation.